A stable patient with PE and no right heart strain or biomarker elevation is in which risk category and what is the initial therapy?

A stable patient with PE and no right heart strain or biomarker elevation is in which risk category and what is the initial therapy?

• A. High risk; Reperfusion therapy
• B. Intermediate risk; Reperfusion therapy
• C. Low risk; Antiplatelet therapy only
• D. Low risk; Just anticoagulation therapy

Answer: (D)

Risk stratification in acute PE uses hemodynamic status, right ventricular function, and biomarkers. A stable patient with no right heart strain and no biomarker elevation is categorized as low risk. In this group, the initial therapy is anticoagulation alone, not reperfusion. Start a rapid-acting anticoagulant such as low-molecular-weight heparin, unfractionated heparin, or fondaparinux, then transition to an oral anticoagulant for long-term treatment. Direct oral anticoagulants are commonly preferred and can often be given without bridging, sometimes even on an outpatient basis. Thrombolysis or other reperfusion therapies are reserved for those with high risk (shock or significant deterioration), and antiplatelet therapy alone is not appropriate for treating PE.

Risk stratification in acute PE uses hemodynamic status, right ventricular function, and biomarkers. A stable patient with no right heart strain and no biomarker elevation is categorized as low risk. In this group, the initial therapy is anticoagulation alone, not reperfusion. Start a rapid-acting anticoagulant such as low-molecular-weight heparin, unfractionated heparin, or fondaparinux, then transition to an oral anticoagulant for long-term treatment. Direct oral anticoagulants are commonly preferred and can often be given without bridging, sometimes even on an outpatient basis. Thrombolysis or other reperfusion therapies are reserved for those with high risk (shock or significant deterioration), and antiplatelet therapy alone is not appropriate for treating PE.